Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Was This $3 Billion Deal a Wise Move for Sanofi?

TheMotleyFool

0 0

Was This $3 Billion Deal a Wise Move for Sanofi?: https://g.foolcdn.com/editorial/images/734203/a-patient-attends-a-doctor-appointment.jpg

Aside from price hikes on their products, pharmaceutical companies have two levers they can pull to potentially juice their profit growth: acquisitions as well as higher research and development spending.

Sanofi (NASDAQ: SNY) recently opted for the former strategy to strengthen its business. In late April, the company completed its acquisition of Provention Bio for $2.9 billion in cash. This raises the following questions: Was the deal a savvy play by Sanofi? And could it be enough to move the needle for the company?

Let's dig into the primary drug, Tzield, that Sanofi picked up from the deal and look at the type 1 diabetes market to find the answers.

Source Fool.com

Like: 0

SNY

Share